PRESS RELEASE_Neuroscience Nordic University Hospital.pdf
Nordic University Hospital Procures Nexstim NBS 6 System for Advanced Neuroscience Research
Press Release, Helsinki, 9 November 2026 at 9 AM (EEST)
Nordic University Hospital Procures Nexstim NBS 6 System for Advanced Neuroscience Research
Nexstim Plc ("Nexstim" or "Company") has received an order for one NBS 6 System from a Nordic university hospital. The system will be used primarily to conduct neuroscientific studies.
Researchers at the hospital selected Nexstim's SmartFocus® navigated TMS technology to support studies requiring accurate and reproducible stimulation targeting. The system further expands Nexstim's presence in the Nordic academic research community.
Mikko Karvinen, CEO of Nexstim, said:
“We are glad to support another leading academic center in advancing neuroscience research. For research applications, accuracy, precision, and reproducibility are essential. Our SmartFocus® nTMS technology enables researchers and clinicians to confidently target an intended location in the brain and document stimulation parameters, helping to strengthen the quality and reliability of research results."
Further information is available on the website www.nexstim.com, or by contacting:
Mikko Karvinen, CEO
+358 50 326 4101
About Nexstim Plc
Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.
Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.
Nexstim’s Diagnostics Business focuses on commercialization of the NBS System 6, which is the only FDA-cleared and CE-marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain.
Nexstim’s Therapy Business markets and sells the NBS System 6 which is FDA-cleared for marketing and commercial distribution for the treatment of Major Depressive Disorder (MDD) in adult and adolescent patients who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode, and as an adjunct for the treatment of adult patients suffering from Obsessive Compulsive Disorder (OCD). In Europe, the NBS System 6 is CE-marked for the treatment of major depression, chronic neuropathic pain as well as post-operative rehabilitation of motor deficits of the upper limb.
Nexstim shares are listed on Nasdaq First North Growth Market Finland.
For more information, please visit https://www.nexstim.com/.